|Articles|January 4, 2012

Psychotropic medications and renal failure

Antidepressants - SSRIs

Escitalopram (Lexapro)

Citalopram (Celexa)

Fluoxetine (Prozac, Sarafem)

Fluvoxamine (Luvox)

Paroxetine (Paxil)

Sertraline (Zoloft)

Antidepressants - Tricyclics

Amitriptyline (Elavil)

Clomipramine (Anafranil)

Desipramine (Norpramin)

Doxepin (Sinequan)

Imipramine (Tofranil)

Nortryptiline (Aventyl, Pamelor)

Antidepressants - Other

Bupropion (Wellbutrin, Zyban)

Duloxetine (Cymbalta)

Maprotiline (Ludiomil)

Mirtazapine (Remeron)

Venlafaxine (Effexor)

Antimanic agents

Lithium (Eskalith, Lithobid, Lithonate)

Antipsychotics - Atypical^a

Aripiprazole (Abilify)

Clozapine (Clozaril)

Olanzapine (Zyprexa)

Quetiapine (Seroquel)

Risperidone (Risperdal)

Ziprasidone (Geodon)

Antipsychotics - Typical

Chlorpromazine (Thorazine)

Haloperidol (Haldol)

Anxiolytics and Hypnotics

Eszopiclone (Lunesta)

Ramelteon (Rozerem)

Zaleplon (Sonata)

Zolpidem (Ambien)

Anticonvulsants

Carbamazepine (Tegretol)

Gabapentin (Neurontin)

Lamotrigine (Lamictil)

Oxcarbazepine (Trileptal)

Phenobarbital (Luminal)

Phenytoin (Dilantin)

Pregabalin (Lyrica)

Topirimate (Topomax)

Valproic acid (valproate or divalproex) (Depakene, Depakote)

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Latest CME

Multimedia

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Ilan Melnick, MD; Alejandro Alva, MD; Linda Trinh, DNP, PMHNP, FNP, MPH

Video

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Psychotropic medications and renal failure

Antidepressants - SSRIs

Antidepressants - Tricyclics

Antidepressants - Other

Antimanic agents

Antipsychotics - Atypical^a

Antipsychotics - Typical

Anxiolytics and Hypnotics

Anticonvulsants

Newsletter

Related Content

AD04 for Alcohol Use Disorder: Favorable Feedback From FDA Following End of Phase 2 Meeting

FDA Grants Fast Track Designation to Pemvidutide for Treatment of Alcohol Use Disorder

End of Phase 2 Meeting With the FDA: Adial Prepares to Advance AD04 for Alcohol Use Disorder

Differences in Experiences Must Influence Interventions

Transformation 2.0: The GLP-1 RAs as Psychiatric Medications?

Latest CME

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Southern Florida Psychiatry Conference

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Patent Issued for Rapid Blood Tests to Differentiate Schizophrenia and Bipolar Disorder

A Critical Catch: Catatonia Due to Multiple General Medical Conditions

When Symptoms Are Not Necessarily Signs of Illness: Rethinking Synchronicity in Psychiatry

Study Finds Semaglutide Is Associated With Improved Cognitive Function in Individuals With Psychiatric Disorders

Tricks and Treats for Psychiatry in This Halloween Season

Psychotropic medications and renal failure

Antidepressants - SSRIs

Antidepressants - Tricyclics

Antidepressants - Other

Antimanic agents

Antipsychotics - Atypicala

Antipsychotics - Typical

Anxiolytics and Hypnotics

Anticonvulsants

Newsletter

Related Content

AD04 for Alcohol Use Disorder: Favorable Feedback From FDA Following End of Phase 2 Meeting

FDA Grants Fast Track Designation to Pemvidutide for Treatment of Alcohol Use Disorder

End of Phase 2 Meeting With the FDA: Adial Prepares to Advance AD04 for Alcohol Use Disorder

Differences in Experiences Must Influence Interventions

Transformation 2.0: The GLP-1 RAs as Psychiatric Medications?

Latest CME

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Southern Florida Psychiatry Conference

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Patent Issued for Rapid Blood Tests to Differentiate Schizophrenia and Bipolar Disorder

A Critical Catch: Catatonia Due to Multiple General Medical Conditions

When Symptoms Are Not Necessarily Signs of Illness: Rethinking Synchronicity in Psychiatry

Study Finds Semaglutide Is Associated With Improved Cognitive Function in Individuals With Psychiatric Disorders

Tricks and Treats for Psychiatry in This Halloween Season

Antipsychotics - Atypical^a